title: The MCS + revision A2 for highly efficient PBSC collection.
abstract: Autologous PBSC transplantation is an integral component of the management of hemato-oncology patients. In order to reduce the number of sessions needed to collect the desired number of repopulating cells there has been significant research activity in developing progressively more and more effective technologies and techniques. Recently our group has been involved in the rejuvenation of the MCS + apparatus for both platelet and PBSC collection. The so called "version A2 protocol" is aimed at collecting PBSC in a very efficient way. This protocol is characterized by high blood flow rates both in the collection and reinfusion (80 ml/min) recirculation (56 ml/min) and collection phases (30 ml/min). Only one recirculation is carried out every 5 cycles and only from 5 to 7 are carried out for a single procedure. Twenty-seven collections were carried out of which 25 were evaluable in terms of PBSC efficiency. These averaged 68.8% in an average procedure time of 3.5-5 h for processing an average of 7,052 ml of blood. The RBC contamination was reduced to approximately 5.02 g of hemoglobin and the average volume of the product to 177 ml. If these results are confirmed, the gap between CFC and DFC PBSC is progressively closing.
authors.affiliation: Immunohematology Service, San Martino University Hospital, Genova, Italy. robertabruni@smartino.ge.it
authors.forename: M
authors.initials: M
authors.lastname: Valbonesi
authors.forename: P
authors.initials: P
authors.lastname: Carlier
authors.forename: A
authors.initials: A
authors.lastname: Bo
authors.forename: P
authors.initials: P
authors.lastname: Stura
authors.forename: S
authors.initials: S
authors.lastname: Massazza
authors.forename: B
authors.initials: B
authors.lastname: Sanfilippo
authors.forename: I
authors.initials: I
authors.lastname: Varinelli
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy / Q000628:therapy; D053456:Caspase 14; D020169:Caspases / Q000008:administration & dosage / Q000494:pharmacology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019337:Hematologic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D007937:Leukapheresis / Q000295:instrumentation / Q000379:methods*; D008297:Male; D010976:Platelet Count; D012449:Safety
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; C506446:CASP14 protein, human; D053456:Caspase 14; D020169:Caspases